20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Krystal Biotech Inc (KRYS) operates in the BIOTECHNOLOGY industry and is headquartered in Pittsburgh, United States with about 295 employees. Its market capitalization is roughly $10 billion. In the fiscal year ended 2025-12-31, KRYS reported $389M in revenue and $205M in net income.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
Interactive charts & full statements → Open the KRYS valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $440M | $389M | $291M | $51M | $0M | $0M | $0M | $0M | $1M | $0M | $0M |
| Gross Profit | $411M | $360M | $270M | $48M | ($4M) | ($3M) | ($2M) | ($1M) | $1M | $0M | $0M |
| Gross Margin % | 93.4% | 92.6% | 93.1% | 93.9% | — | — | — | — | 86.3% | — | — |
| Operating Income (EBIT) | $197M | $161M | $66M | ($110M) | ($145M) | ($68M) | ($33M) | ($22M) | ($12M) | ($5M) | ($1M) |
| Operating Margin % | 44.8% | 41.4% | 22.6% | -216.4% | — | — | — | — | -1160.3% | — | — |
| Net Income | $241M | $205M | $89M | $11M | ($140M) | ($70M) | ($32M) | ($19M) | ($11M) | ($8M) | ($1M) |
| Net Margin % | 54.8% | 52.6% | 30.7% | 21.6% | — | — | — | — | -1060.3% | — | — |
| EBITDA | — | $196M | $110M | ($91M) | ($117M) | ($66M) | ($30M) | ($18M) | ($11M) | ($5M) | ($1M) |
| Earnings Per Share (EPS) | $8.00 | $6.84 | $3.00 | $0.39 | $-5.49 | $-3.13 | $-1.71 | $-1.20 | $-0.97 | $-1.48 | $-0.27 |
| Shares Outstanding (M) | — | 30M | 30M | 28M | 25M | 22M | 19M | 16M | 11M | 5M | 4M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $119M | $116M | $107M | $98M | $96M | $88M | $91M | $84M | $70M |
| Gross Profit | $113M | $110M | $96M | $92M | $89M | $83M | $86M | $77M | $64M |
| Gross Margin % | 95.0% | 94.6% | 89.8% | 94.2% | 92.5% | 94.3% | 94.6% | 92.0% | 91.5% |
| Operating Income (EBIT) | $58M | $54M | $44M | $41M | $39M | $36M | $41M | $22M | $9M |
| Operating Margin % | 48.7% | 46.1% | 41.5% | 42.3% | 40.9% | 41.0% | 45.4% | 26.8% | 12.2% |
| Net Income | $55M | $56M | $51M | $79M | $38M | $36M | $45M | $27M | $16M |
| Net Margin % | 46.2% | 48.1% | 48.0% | 81.2% | 39.9% | 40.5% | 49.9% | 32.4% | 22.1% |
| EBITDA | — | $63M | $40M | $50M | $48M | $45M | $50M | $36M | $23M |
| Earnings Per Share (EPS) | $1.79 | $1.83 | $1.72 | $2.66 | $1.29 | $1.20 | $1.52 | $0.91 | $0.53 |
| Shares Outstanding (M) | — | 31M | 30M | 30M | 30M | 30M | 30M | 30M | 30M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $273M | $201M | $123M | ($89M) | ($101M) | ($48M) | ($26M) | ($19M) | ($9M) | ($4M) | ($1M) |
| Capital Expenditures (CapEx) | $15M | $12M | $4M | $12M | $53M | $68M | $15M | $6M | $2M | $0M | $0M |
| Free Cash Flow (FCF) | $257M | $189M | $119M | ($101M) | ($154M) | ($116M) | ($41M) | ($25M) | ($12M) | ($4M) | ($1M) |
| FCF Margin % | 58.4% | 48.5% | 41.0% | -198.4% | — | — | — | — | -1137.2% | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $75M | $80M | $78M | $40M | $53M | $31M | $53M | $59M | ($4M) |
| Capital Expenditures (CapEx) | $4M | $7M | $2M | $2M | $2M | $6M | $1M | $1M | $1M |
| Free Cash Flow (FCF) | $71M | $73M | $75M | $38M | $51M | $25M | $52M | $58M | ($5M) |
| FCF Margin % | 59.7% | 62.9% | 70.4% | 38.8% | 52.9% | 28.1% | 57.1% | 69.0% | -7.5% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.5B | $1.3B | $1.1B | $818M | $558M | $626M | $311M | $209M | $116M | $50M | $2M |
| Cash & Cash Equivalents | $428M | $496M | $345M | $358M | $162M | $341M | $268M | $188M | $104M | $50M | $2M |
| Total Liabilities | $142M | $114M | $109M | $40M | $36M | $33M | $19M | $6M | $3M | $1M | $2M |
| Total Debt (Short + Long-Term) | — | $2M | $1M | $1M | $2M | $1M | $8M | $0M | $0M | $0M | $2M |
| Total Shareholders' Equity | $1.4B | $1.2B | $946M | $779M | $522M | $594M | $292M | $203M | $113M | $49M | $0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive KRYS viewer.
This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी
About TickerBase · Data methodology & sources · Privacy · Terms